Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen immune response sub-study in chronic hepatitis B
ISRCTN11489455Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Oct 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Chronic Hepatitis B (CHB) comparing Bepirovirsen with Placebo (2 arms). Primary endpoint: HBV-specific CD8 T-cell phenotype. Started Oct 2025; status: recruiting.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ISRCTN11489455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11489455.